Posaconazole Oral Suspension Articles
FDA approves Merck' & Co’s Dulera for asthma in patients; firm initiates Ph II trial of Chagas drug candidate
25 June 2010
US IDSA's IFI guidelines recommend S-P's Noxafil
11 February 2008
NCCN advocates Noxafil for IFI in cancer patients
26 March 2007
S-P unveils landmark Noxafil data
29 January 2007
S-P's Noxafil cleared by European Commission
20 November 2006
US FDA clears S-P's Noxafil for expanded indication
30 October 2006
S-P's antifungal Noxafil gets FDA OK
25 September 2006
US FDA grants priority review to Schering-Plough's Noxafil
27 February 2006
S-P launches Noxafil in the UK for refractory IFI
13 February 2006
S-P's new antibiotic performs well in trials
19 December 2005
EMEA OKs Schering-Plough's Noxafil
8 August 2005
S-P's posaconazole NDA accepted for FDA review
19 July 2004
Positive Ph III data for Schering-Plough's Noxafil
4 August 2003
Showing 1-17 of 17 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
